TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation

• Published in: Molecular cancer research Vol. 22; no. 12; pp. 1102 - 1116
• Main Authors: Zhang, Yahui, Ren, Yidan, Dong, Guoying, Jiao, Qinlian, Guo, Nan, Gao, Ping, Li, Ya, Wang, Yunshan, Zhao, Wei
• Format: Journal Article
• Language: English
• Published: United States 03.12.2024
• Subjects: Animals; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - metabolism; Carcinoma, Hepatocellular - pathology; Cell Line, Tumor; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; Drug Resistance, Neoplasm - genetics; Female; Gene Expression Regulation, Neoplastic - drug effects; Humans; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - metabolism; Liver Neoplasms - pathology; Male; MAP Kinase Kinase Kinases - genetics; MAP Kinase Kinase Kinases - metabolism; Mice; Mice, Nude; Sorafenib - pharmacology; Sorafenib - therapeutic use; TEA Domain Transcription Factors; Transcription Factors - genetics; Transcription Factors - metabolism; Transcriptional Activation; Xenograft Model Antitumor Assays

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, yet the effectiveness of treatment for patients with HCC is significantly hindered by the development of drug resistance to sorafenib. Through the application of accessibility sequencing to examine drug-resistant HCC tissues,...